海角社区

Auslander focuses on developing machine learning methods to understand genetic and infectious factors that drive cancer evolution and identify patterns that can improve cancer diagnosis and treatment.

Auslander earned her B.S. in computer science and biology from Tel Aviv University and continued her studies in Maryland, where she obtained a computer science Ph.D. from the University of Maryland with a combined fellowship at the National Cancer Institute. She received postdoctoral training at the National Center of Biotechnology Information (NCBI) and joined The Wistar Institute in 2021 as an assistant professor.

Gardini studies the epigenetic control of transcription during cell differentiation and oncogenesis.

Born and raised in Italy, Gardini obtained a B.S./M.S. in medical biotechnology at the University of Bologna and attended the graduate school of Molecular Medicine at the University of Milan. He trained as a postdoctoral fellow with Dr. Ramin Shiekhattar at the Center of Genomic Regulation in Barcelona, The Wistar Institute and the University of Miami Medical School. He joined Wistar as an assistant professor in 2015. Gardini is a scholar of the Leukemia Research Foundation and the American Cancer Society.

Murphy studies the genetics of the p53 tumor suppressor protein. Her laboratory focuses on genetic variants of p53 that exist in populations of African-descent (P47S and Y107H) and Ashkenazi Jewish descent (G334R). Her work seeks to understand the impact of these genetic variants of p53 on cancer risk and the efficacy of cancer therapy. She also seeks to identify personalized medicine approaches for tumors with these variants. Therefore, her work has direct relevance for improving the cancer prognosis and therapy of African and Ashkenazi Jewish Americans. Murphy also studies the cancer-survival protein HSP70. Her lab employs a novel series of HSP70 inhibitors for melanoma and colorectal cancer therapy.

Murphy obtained a B.S. degree in biochemistry at Rutgers University, followed by a doctorate in molecular biology at the University of Pennsylvania School of Medicine. In 1994, she began postdoctoral research at Princeton University in the laboratory of Arnold J. Levine, Ph.D., the co-discoverer of p53. In 1998, Murphy became an Assistant Professor at Fox Chase Cancer Center, where she was promoted to Associate Professor in 2003, and Full Professor in 2011. She joined The Wistar Institute in 2011 and became Program Leader of the Molecular and Cellular Oncogenesis Program in 2012. Murphy is an adjunct professor at Drexel University College of Medicine and The Perelman School of Medicine at the University of Pennsylvania.